State Government

Title Due Date Maximum Award Amount Sort descending Description
Limited Competition: Environmental influences on Child Health Outcomes (ECHO) Cohort Study Sites for Pediatric Follow Up. Clinical Trial Not Allowed (UG3/UH3) Varies

This funding opportunity announcement (FOA) invites applications to renew current ECHO Cohort Study Sites to extend the capacity of the ECHO Cohort to further investigate the roles of a broad range of early exposures from society to biology on ECHOs five key child health outcome areaspre-, peri- and postnatal, upper and lower airways, obesity, neurodevelopment, and positive healthamong diverse populations. The objectives of this FOA are to solicit applications to 1) lead collaborative ECHO Cohort science, 2) follow up existing ECHO Cohort participants, and 3) implement the ECHO Cohort Data and Biospecimen Collection Protocol using the ECHO Cohort consortiums central data capture system, e.g., REDCap Central. This FOA does not support site-specific analyses and science. Only current ECHO Cohort awardees are eligible to apply. This new funding period will be 7 years in duration provided successful performance in the UG3 phase and the UH3 phase. This FOA runs in parallel with companion FOAs that solicit applications for Cohort Study Sites for a limited competition of follow-up of existing ECHO Cohort participants AND of recruitment of new pregnant participants, their resulting offspring, and, if available, the conceiving partner (RFA ZZZZ), for ECHO Cohort Study Sites only for an open competition of recruitment of new pregnant participants, their resulting offspring, and, if available, the conceiving partner (RFA YYYY), for an ECHO Coordinating Center (RFANNNN), for an ECHO Data Analysis Center (RFA NNNN), for an ECHO Measurement Core (RFA NNNN), and for an ECHO Laboratory Core (RFA NNNN).

https://www.grants.gov/web/grants/view-opportunity.html?oppId=343296
NCI Pathway to Independence Award for Outstanding Early Stage Postdoctoral Researchers (K99/R00 - Independent Clinical Trial Required) Varies

The purpose of the NCI Pathway to Independence Award for Outstanding Early Stage Postdoctoral Researchers (K99/R00) program is to increase and maintain a strong cohort of new and talented, NCI-supported, independent investigators. This program is designed for postdoctoral fellows with research and/or clinical doctoral degrees who do not require an extended period of mentored research training beyond their doctoral degrees. The objective of this award is to facilitate a timely transition of these fellows from their mentored, postdoctoral research positions to independent tenure-track (or equivalent) faculty positions. The program will provide independent NCI research support during this transition to help awardees to launch competitive, independent research careers. Researchers in the scientific areas of data science and cancer control science are especially encouraged to apply. This Funding Opportunity Announcement (FOA) is designed specifically for candidates proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Those not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to the companion FOAs (RFA-CA-22-035).

https://www.grants.gov/web/grants/view-opportunity.html?oppId=343548
NIDA REI: Reaching Equity at the Intersection of HIV and Substance Use: Novel Approaches to Address HIV Related Health Disparities in Underserved Racial and/or Ethnic Populations (R01 Clinical Trial Optional) Varies

This Funding Opportunity Announcement (FOA) is a part of NIDAs Racial Equity Initiative (REI), a multi-year, multi-pronged effort to eliminate racial inequities in NIDAs workplace, scientific workforce, and research portfolio. The purpose of this initiative is to stimulate new observational and intervention research on structural factors, organizational practices, policies, and other social, cultural, and contextual influences that lead to inequities at the intersection of HIV and substance use among underserved racial/ethnic populations affected by persistent HIV disparities. Research that addresses the multiple dimensions of individuals identity (e.g., race, ethnicity, gender, sexual orientation, gender identity) and social systems as they intersect with one another is encouraged.

https://www.grants.gov/web/grants/view-opportunity.html?oppId=343933
R9 BIL High-Priority Regional Invasive Species Projects (Non-Federal Lands) Varies

As part of the Bipartisan Infrastructure Law's (BIL) broader ecosystem restoration objective, the non-federal lands portion of the invasive species provision enables the USDA-Forest Service, States, and other agencies to strategically sustain the health of forest ecosystems or tree species with high ecological value by taking stronger action in the early phases ofthe invasion curve at regional or sub-regional scales and at points of entry. Specifically, we aim towork collaboratively to scale-up the implementation of management actions in the field for the prevention of introductions or spread, prevention of damage, early detection of introductions, rapid response and eradication of invasive forest insects, worms, pathogens, and plants. It is expected that new projects will be complementary to existing cooperative and federal forest health protection programs and will sustain high value forest ecosystems or tree species (see, e.g., multi-state priority areas identified in State Forest Action Plans (SFAPs) or Northeast-Midwest State Foresters Alliance, Forest Health Committee (NMSFA FHC) 2021 priority needs document).

https://www.grants.gov/web/grants/view-opportunity.html?oppId=343997
Revision Applications for Incorporation of Novel NCI- Supported Technology to Accelerate Cancer Research (U01 Clinical Trial Optional) Varies

The purpose of this Funding Opportunity Announcement (FOA) is to encourage revision applications (formerly called "competing revisions") from currently funded NCI U01 research projects. The applicants should propose to expand upon the original research question(s) or otherwise accelerate progress for the parent study by incorporating a new technical approach or instrument developed through support from the NCI Innovative Molecular Analysis Technologies (IMAT) program. Awards from this FOA are meant to incentivize independent validation and accelerate the suitability of these emerging technologies for appropriate research communities.As a component of the NCI IMAT program, this FOA aims to promote interdisciplinary collaboration in the development of innovative tools and methods that enable cancer research and accelerate scientific discovery.

https://www.grants.gov/web/grants/view-opportunity.html?oppId=344764
Genomic Community Resources (U24 Clinical Trial Not Allowed) Varies

To facilitate genomic research and the dissemination of its products, NHGRI supports genomic resources that are crucial for basic research, disease studies, model organism studies, and other biomedical research. Awards under this FOA will support the development and distribution of genomic resources that use cost-effective approaches and will be valuable for the broad research community. Such resources include (but are not limited to) databases and informatics resources (such as human and model organism databases, ontologies, and analysis toolsets), comprehensive identification and collections of genomic features (such as functional genomic elements), and standard data types produced using central sets of samples (such as structural variants in 1000 Genomes or GTEx samples).

https://www.grants.gov/web/grants/view-opportunity.html?oppId=345076
Translational Centers for Microphysiological Systems (TraCe MPS) (U2C Clinical Trials Not Allowed) Varies

The purpose of this funding opportunity announcement (FOA) is to establish Centers to support research that will accelerate the translational use of Microphysiological Systems (MPS) in drug development through regulatory acceptance and adoption for industrial use, by establishing MPS that are fit-for-purpose for industry needs and have specific defined contexts of use (CoUs) and will be developed with consideration of applicable expectations to achieve regulatory approval. For this FOA, the term drugs refers to both human pharmacological and biological products unless otherwise specified. These Centers will further the development of MPS as drug development tools (DDTs) that, once qualified, will be made publicly and commercially available to fill unmet needs in drug development.

https://www.grants.gov/web/grants/view-opportunity.html?oppId=345135
NIDA Program Project Grant Applications (P01 Clinical Trial Optional) Varies

This Funding Opportunity Announcement (FOA) announces the availability of support for collaborative research by multi-disciplinary teams which is of high priority to NIDA and leads to synergistic outcomes based on the synthesis of multiple research approaches. The NIDA Program Projects funding opportunity will support research in which the funding of three or more highly meritorious projects as a group enriches both the component projects and the overall program to offer significant scientific advantages over supporting the same projects as individual research grants (i.e., synergy). For the duration of the award, each Program must consist of a minimum of three research projects focused on issues critical to advance the mission and goals of NIDA.

https://www.grants.gov/web/grants/view-opportunity.html?oppId=345314
FY 2023 Competitive Funding Opportunity; Low or No Emission Vehicle Program Varies

The Federal Transit Administration (FTA) announces the availability of approximately $1.22 billion in competitive grants under the Low or No Emission Grant Program (Low-No Program) for the purchase or lease of zero-emission and low-emission transit buses, including acquisition, construction, and leasing of required supporting facilities. Synopses and full announcement will be posted on Grants.gov as opportunity FTA-2023-002-TPM-LWNO. Proposals must be submitted electronically through Grants.gov website by 11:59 PM Eastern Time April 13, 2023.

https://www.grants.gov/web/grants/view-opportunity.html?oppId=345639
Maintaining and Enriching Environmental Epidemiology Cohorts to Support Scientific and Workforce Diversity (U24 Clinical Trial Not Allowed) Varies

The purpose of this Funding Opportunity Announcement (FOA) is to solicit grant applications that propose to: (1) support the maintenance and resource infrastructure enrichment for existing Environmental Epidemiology Cohorts (EECs) and to (2) enrich data management and data sharing activities to promote widespread data sharing and scientific collaborations to be inclusive of under-resourced minority-serving institutions and under-represented minority researchers.The ultimate goal is to maintain and maximize NIEHS cohort investments within the environmental epidemiology community by improving data collection on under-represented populations in environmental health studies, strengthening workforce diversity and promoting greater scientific collaboration.

https://www.grants.gov/web/grants/view-opportunity.html?oppId=346134